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Abstract
Background: The lack of a uniform way for qualitative and quantitative evaluation of vaccine candidates under
development led us to set up a standardized scheme for vaccine eﬃcacy and safety evaluation. We developed and
implemented molecular and immunology methods, and designed support tools for immunization data storage and
analyses. Such collection can create a unique opportunity for immunologists to analyse data delivered from their
laboratories.
Results: We designed and implemented GeVaDSs (Genetic Vaccine Decision Support system) an interactive system
for eﬃcient storage, integration, retrieval and representation of data. Moreover, GeVaDSs allows for relevant association
and interpretation of data, and thus for knowledge-based generation of testable hypotheses of vaccine responses.
Conclusions: GeVaDSs has been tested by several laboratories in Europe, and proved its usefulness in vaccine
analysis. Case study of its application is presented in the additional ﬁles. The system is available at: http://gevads.cs.
put.poznan.pl/preview/ (login: viewer, password: password).
Background
Immune response & vaccination principles
Vaccines are eﬀective tools to prevent infectious diseases
in humans or animals [1,2]. A vaccine typically contains
an antigen mixture that stimulates a body’s immune sys-
tem to recognize the agent as foreign, inducing speciﬁc
immune responses and memory for long-term protec-
tion against the disease-causing microorganisms. Vac-
cines can be prophylactic (to prevent a future infection)
or therapeutic (e.g. vaccines against cancer). Following
vaccination, both innate and adaptive immune system
components synergize to elicit an immune response.
Antigen-presenting cells - notably dendritic cells - take up
antigens and traﬃc to the draining lymph nodes where
they present processed antigens to naive CD4+ and CD8+
T lymphocytes. Naive T-cells are stimulated to prolifer-
ate and diﬀerentiate into eﬀector and memory T-cells.
Activated eﬀector and memory CD4+ T-cells provide
help to B-cells to mount antibody responses, and help
naive CD8+ T-cells to enhance their clonal expansion and
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diﬀerentiation into cytotoxic CD8+ T lymphocytes (CTL).
The quality of the vaccine-induced immune response
depends on several factors, e.g. antigen nature, route of
administration, antigen presentation, vaccine preparation
adjuvants, or timing between challenges.
Vaccine development & evaluation
Usually, the eﬀectiveness of vaccination is ascertained
when vaccinated individuals exposed to infection are pro-
tected. To be eﬀective, a vaccine should trigger eﬃcient
activation of antigen-presenting cells to initiate antigen
processing and presentation to T-cells, as well as activa-
tion of T and B-cells (production of antibodies, generation
of memory B-cells, memory CTL and memory CD4+
T-cells). Several immune parameters can be measured
to monitor the immune response, including antigen-
speciﬁc and neutralizing antibodies, antigen-speciﬁc T-
cell expansion, CTL activity and cytokine production.
Dendritic cell state of activation can be assessed by tran-
scriptome analysis. A central goal of vaccine research
is to identify whether an early vaccine-induced immune
response is predictive of later protection [3,4]. An immune
response can be used for guiding vaccine development,
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for predicting vaccine eﬃcacy in diﬀerent settings, and for
setting vaccination policies and regulations.
The new generations of recombinant vaccines comprise
peptides, DNA vaccines, viral or bacterial delivery system
and Virus Like Particles. Although enormous progress has
been made in the process of vaccine development, there
is still a need to standardize the qualitative and quanti-
tative evaluation of new vaccines, to develop a platform
of novel recombinant genetic vaccines using genomic and
proteomic information and to create interactive systems
to store all types of experimental data together (such as
immune response parameters stated above) with statisti-
cal and analytical tools to support scientists during their
experiment. The above goals were achieved by the Com-
puVac consortium [5] established within a project funded
under FP6 EC programme. As one of the key deliverable of
this project, a new web platform called GeVaDSs (Genetic
Vaccine Decision Support system) has been designed and
implemented. GeVaDSs is accessible for scientiﬁc com-
munity. GeVaDSs allows one to (i) ﬁnd the description
of stored experiments, (ii) create new experiments and
store experimental data, and (iii) visualize and cross-
compare the results of theses experiments. The construc-
tion and the development of the GeVaDSs is a ﬁrst trial
to standardize and describe the whole process of vaccine
development, making it a really challenging aspect of the
CompuVac project.
Although it is diﬃcult to ﬁnd eﬃcient system for vac-
cine analysis, it is worth to mention results of VIOLIN
initiative (Vaccine Investigation and Online Information
Network) [6,7]. It is a system for storing and analyzing
published vaccine data. It has been developed for data
mining, curation and analysis of results for commercially
available vaccines, as well as vaccine candidates on the
early stage of development. The main diﬀerence between
VIOLIN and the one presented in GeVaDSs is the level of
data collected in the system and the analysis possible. The
ﬁrst system gives a researcher an opportunity to gather
data concerning a particular vaccine. The second one is
useful at the level of laboratory tests of those vaccine.
GeVaDSs was developed to store raw experimental results
and presents them in a user friendly form. It allows for
a comparison of the organism response to a vaccination
at diﬀerent levels like T-cell and B-cell. Furthermore, the
inﬂuence of the vaccine on the selected gene expression
can be determined in the Molecular Signature module
and the eﬃcacy of the immunization protocol used, is
analyzed in the Vector Challengemodule.
Implementation
The system was implemented using the Adobe Flex 3
technology and Action Script 3 language on the client
side (interface, logic mechanisms), whereas the server side
interface was implemented using mainly the PHP script
language, in addition to other languages like Perl, R and
Java. All data processed by the GeVaDS system are stored
in the PostgreSQL relational database.
Structure of the system
GeVADSs consists of two groups of modules: vaccine-
related modules, which are designed to process the bio-
logical data, and support modules, which are responsible
for data entry, report generation and data access. The
simpliﬁed structure of the system is presented in Figure 1.
The vaccine-related modules are: T-cell, B-cell, Molec-
ular Signature, Vector Challenge, Evaluation and Dictio-
naries (the latter is shared by all other modules and is not
shown in Figure 1). Their brief descriptions are presented
below. The support modules are: input for introducing
data, output for viewing the results, Quality Check - for
checking the quality of introduced data, reports which
allows the user to generate a report for requested data
as a pdf ﬁle, and the system access and privileges. All of
the support modules, excluding the last one, are designed
separately for each of the vaccine-related modules. For
example, GeVaDSs consists of T-cell input module, B-
cell input module etc. Obviously, input modules are very
similar.
Dictionaries
As mentioned above, Dictionaries is a general module,
which is shared by all modules to unify terms and deﬁni-
tions used in experiments deﬁnition. It deﬁnes basic terms
like species, animal models, antigens... used across the
whole system. However, some parts are crucial to under-
stand the idea of GeVaDSs, and therefore are presented
below in more details.
Hierarchy of vaccine vectors. Hierarchy of vaccine vec-
tors has been created on the basis of their biological
features. Each vector in the hierarchy has a standard-
ized description which contains information about its
producer, production type, antigen, the expected type
of immunological response, etc. The standardization of
vectors enables their evaluation based on the quality of
vaccine-induced immune responses. The GeVaDS system
not only provides a set of deﬁned vectors arranged in a
hierarchy, but also enables a user to store and manage his
own vectors and put them into the hierarchy. The Vectors
module makes it possible to edit information about vec-
tors. The main view of this module is divided into two
main parts: the tree of vector categories and a list of vec-
tors in a selected position of the vector category subtree
(Figure 2).
Immunization protocol. The Immunization protocol
module has been designed to standardize and store data
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Figure 1 The structure of the GeVaDS system. The simpliﬁed structure of the GeVaDS system with main modules and connections among them.
Figure 2 Vectormodule - main view. The Vector module main view presents the tree of vector categories and a list of vectors in a selected
position of the vector category subtree.
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about immunization protocols and to deﬁne immuniza-
tion process. An immunization protocol is created by a
careful description of each inoculation stage (schedule,
vector, dose, administration route). Hence, each immu-
nization protocol is standardized in the system. Once
a protocol has been created, it can be displayed in the
form of a time chart, on which timepoints of inocula-
tions are represented. Each of these timepoints has a
detailed description presented as a tooltip (displayed on
the mouse-over action). The list of deﬁned immuniza-
tion protocols is presented on the grid with the most
signiﬁcant parameters displayed in columns. A search ﬁl-
ter ﬁlters immunization protocol entries based on user
demands. The main view of this module is presented
in Figure 3.
Challenge protocol. The Challenge protocol module has
been designed to deﬁne and store information about chal-
lenge protocols used to evaluate the susceptibility to an
infectious challenge with a pathogen of a population of
individuals, vaccinated or not. A challenge protocol is
created by deﬁning information provided about the chal-
lenge, i.e. animal description, dates or intervals of viremia,
T-cell response and/or B-cell response. Hence, each chal-
lenge protocol is standardized in the system. Protocols
already deﬁned can be displayed as time charts. The
meaning of particular actions is the same as in the case of
the immunization protocol. The main view of this module
is presented in Figure 4.
Organization of experiments. Experiment is the basic
assessment unit in the system. It describes a vaccina-
tion experiment conducted in the laboratory, and stores
data such as: information about experiment creator, date,
default parameters of the experiment (default animal
model, default sex, default age...) which would be inher-
ited by the experimental group unless otherwise speciﬁed.
Default parameters are thus helpful when many experi-
mental groups are similar to each other only with slight
diﬀerences. Each experiment introduced into the system
involves several experimental groups. An experimental
group consist of a set of uniform individuals (same age,
same sex, same animal model...) for which the immuniza-
tion followed a given protocol.
There are ﬁve types of experimental group. Each exper-
imental group can be one of the following types:
• experimental vaccine - a group of individuals being
immunized with an experimental vaccine to be tested.
• naive/control - a group immunized with an empty
vector, without antigen.
• negative control - no immunization.
Figure 3 Immunization protocolmodule - main view. The Immunization protocolmain view presents the list of deﬁned immunization protocols
and the time chart representing deﬁned inoculations.
Blazewicz et al. BMC Bioinformatics 2012, 13:91 Page 5 of 16
http://www.biomedcentral.com/1471-2105/13/91
Figure 4 Challenge protocolmodule - main view. The Challenge protocolmain view presents the list of deﬁned challenge protocols and the time
chart displaying deﬁned dates at which the animal survival is measured.
• Internal Standard - a group being immunized using a
predetermined standard immunization protocol
based on the selected internal standards, which
constitutes a benchmark for comparison of diﬀerent
experiments (e.g. carried out in diﬀerent laboratories).
The system enables to generate an Excel template of
experiment (Figure 5) after introducing into the system
very basic information to deﬁne the experiment. The
template provides a very convenient way of introducing all
results of an experiment to the system by simply copying
and pasting results from other ﬁles, and then importing
the template into the system. Templates constitutes parts
of the input modules.
System access & privileges. The usage of the GeVaDS
system requires authorization. This mechanism not
only protects the system against accidental usage or
Figure 5 Example of experimental data template. The template provides a very easy way of introducing all results of an experiment to the
system by simply copying and pasting results from other ﬁles, and then importing the template into the system.
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misbehavior, but also ensures safety of data stored in the
system. Authorized users have access to modules depend-
ing on the role assigned by the system administrator (e.g.
admin, lab manager, etc). Privileges deﬁned in the sys-
tem are divided into two groups: those connected with
the access to particular modules or with performing some
actions, and those connected with the user data. Privi-
leges for the ﬁrst group could be assigned by the system
administrator (they are called Roles). The second type of
privileges are managed by users themselves. Each user
has a full access to his/her own data (as the owner of the
data), a read-only access to public data and access to data
shared by other users. The owners can make their data
publicly accessible or they can give a custom access to
other users. However, by default, the lab manager (a spe-
cial role) of a given laboratory has full access to all data of
users belonging to his/her laboratory.
Module description
Quality Control module
Quality Control module is responsible for checking the
quality and correctness of the data introduced by the user
as well as the composition of experiments. The quality
control process is based on a set of quality rules. Each
rule is assigned a unique number, information about the
data module to which the rule should be applied (T-cell,
B-cell, Molecular Signature etc.) and the level of applica-
tion (experiment, experimental group, individual or data
value). Depending on the level of application, there are
rules responsible for checking the deﬁnition of experi-
ments or experimental groups (i.e.: Have the laboratory
& date of experiment been provided? Have experimen-
tal control groups been created? Is each experimental
group large enough for statistical analysis?...), as well as
controlling every single value of all attributes (i.e.: Are
interferon gamma production values provided as per-
centages? Are the naive experimental group results in
acceptable ranges?...). Reference values of attributes deﬁn-
ing acceptable ranges have been deﬁned by immunology
experts.
The procedure of quality control of an experiment (or
an experimental group) should be launched by the user
before data analysis. During this procedure, in case a
rule is broken the system generates an error message.
At the end of the procedure a report listing all mes-






Each error is marked with an icon in the ﬁrst column of
the report (see Figure 6).
After the quality control procedure, each experiment, as
well as experimental group, receives a quality status. Five
diﬀerent quality statuses have been deﬁned:
• Not Checked (NC) - the default status before
launching the quality control procedure. Quality
status is reset to NC after any revision.
• Rejected (R) - the data for experimental group or
experiment have some fatal errors and therefore the
data need to be corrected before proceeding.
• Pending (P) - the data for experimental group or
experiment have some serious errors; the user may
Figure 6 Quality control report - list of messages. An example list of messages of an experiment quality control report.
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decide to manually enforce the quality status from
Pending to Rejected or User.
• User (U) - the data for experimental group or
experiment have been manually validated by the user
(see Pending).
• Auto (A) - the data for experimental group or
experiment have no fatal nor serious errors and have
been automatically validated by the system.
Experiments or experimental groups with the status
Auto or User are assumed to be valid and ready for further
analysis. Figure 7 shows an example summary report.
Each experiment may also have one of two quality
ﬂags:
• E-ready - means that the experiment has reliable data
and involves correct experimental groups that can be
analyzed. The E-ready ﬂag is received when at least
one Naive and one Internal Standard or Experimental
Vaccine groups have the Auto or User quality
status.
• EC-ready - means that data stored for this
experiment can be analyzed and compared against
other experiments. The EC-ready ﬂag is received
when at least one Naive, one Internal Standard, and
one Experimental Vaccine groups have the Auto or
User quality status.
T-cell module
T-cell module analyzes the response mediated by T lym-
phocytes over time. This response is described by the fol-
lowing parameters: expansion of vaccine antigen-speciﬁc
T-cells (%), memory phenotype (%), CTL activation (% of
intracellular interferon gamma positive CD8+ T-cells) and
cytotoxicity (% of speciﬁc lysis).
T-cell response values can be introduced in two ways:
manually, by introducing values using the T-cell input
submodule or automatically, by generating and uploading
a standardized template (a Microsoft Excel ﬁle) that can
be ﬁlled by the user by copy-paste from his/her worksheet
and then uploaded back into the system. After check-
ing for consistency, data is automatically inserted and
quality-controlled.
These alternative input methods raise the problem of a
possible conﬂict between automatic uploading of a tem-
plate and manual edition of the experiment after tem-
plate generation. This problem has been circumvented
by stamping both the template and experiment at the
time of template generation, the experiment stamp being
modiﬁed during any manual edition. Therefore, in the lat-
ter case, an older template version will be rejected for
uploading.
Once data have been properly uploaded and quality-
controlled, they can be analyzed with T-cell response
submodules:
• Individual submodule, where data for individuals can
be displayed as charts and tables. Figure 8 shows an
example chart for a given individual,
• Experimental group submodule, where data for all
individuals within an experimental group can be
analyzed. This submodule displays charts and tables
for average (Figure 9) and individual (Figure 10)
values for the selected experimental group,
• Experiment submodule, where data for experimental
groups can be compared. In order to facilitate result
evaluation, this submodule oﬀers several graphical
and tabular outputs, e.g. bar charts (Figure 11), radar
charts (not shown).
Figure 7 Quality control report - summary. An example summary of an experiment quality control.
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Figure 8 T-cell responsemodule - individual chart. An example
chart taken from Individual submodule of T-cell responsemodule
representing the change of memory phenotype over time.
• Comparison of Experiment submodule where data
for experimental groups belonging to diﬀerent
experiments also can be compared. Such a
comparison is possible when the experimental groups
are related to the Internal Standard groups
immunized following the same Immunization
Protocol. Results of selected experimental groups are
presented as ratios against the selected Internal
Standard group results. Example bar and radar charts
are presented in Figures 12 and 13, respectively.
B-cell module
B-cell response module analyzes the response mediated
by B lymphocytes in terms of antibody production and
antibody neutralization activity. The results are pre-
sented as sigmoid curves obtained after linear regression
for serum titration [8]. Since calculating the sigmoid is
computationally time consuming, the system calculates
the sigmoid once on ﬁrst request. Linear regression results
are stored in the database.
For each experiment, the following parameters should
be deﬁned:
• serum descriptions (typically marked as S0, S1...) -
which are deﬁned for diﬀerent days of measurement,
• serum dilutions (marked as 1/20, 1/100...) - which are
deﬁned for diﬀerent dilutions tested.
The structure of the B-cell response module is very
similar to that of the T-cell response module. The main
diﬀerence concerns the data insertion requirement since
the deﬁnition of the experiment is a prerequisite step
before template creation, as well as the deﬁnition of serum
descriptions and dilutions. Once experiment is properly
described, the B-cell template is found very convenient
with regard to the much higher amount of data to be
provided for titration experiments.
The sigmoid titration curve is expressed as follows:
• with the sigmoid formula (Eq. 1) [8],
• with a table with the sigmoid parameters values (not
shown),
• with a graphical representation of the sigmoid
(Figure 14).
%neutralization(dilution) = bottom








• top - is a maximal curve asymptote,
Figure 9 T-cell responsemodule - average results for an experimental group. An example chart taken from Experimental group submodule of
T-cell responsemodule representing average values for T-cell response attributes.
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Figure 10 T-cell responsemodule - summary of individual values for an experimental group. An example chart and data table taken from
Experimental group submodule of T-cell responsemodule representing values for individuals of a selected experimental group.
Figure 11 T-cell responsemodule - experimental values from a selected experiment. An example bar chart taken from Experiment submodule
of T-cell responsemodule representing average values for experimental groups (after normalization against naive experimental group data). See
GeVaDSs Manual for detailed description of calculation [14].
Figure 12 T-cell responsemodule - experimental values from a selected experiment compared to the Internal Standard. An example bar
chart representing experimental group results normalized against Internal Standard experimental group results (displayed as the Internal Standard
reference line).
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Figure 13 T-cell responsemodule - radar chart for a selected
experiment in comparison to the Internal Standard. An example
radar chart representing experimental group results normalized
against Internal Standard experimental group results (see Internal
Standard reference greyed area). The axis of the chart are oriented in
the way that the best values for a particular parameter are positioned
outside. Therefore, the better results for an experimental group the
bigger area covered by the polygon for this group on a radar chart.
• bottom - is a minimal curve asymptote,
• HillSlope - denotes the steepness of the curve,
• EC50 - denotes the dilution that produces the
neutralization halfway between the bottom and top
response levels.
Again, several output submodules can be distinguished
in the B-cell module.
Individual submodule allows the user to analyze the
sigmoid for a single individual. Charts display the neu-
tralization per dilutions for Ag-speciﬁc pseudoparticles
(Ag-pp) and Control Ag-irrelevant control pseudoparticle
(CTR-pp) (Figure 15).
Experimental group submodule shows the sigmoid for
all individuals assigned to the selected group, and the aver-
age sigmoid (determined by a linear regression for all data
points). The results also contain the set of charts with
the neutralization per dilutions for Ag-pp and CTR-pp
together with the average values of dilutions.
Experiment submodule shows the outcome in the same
way as the Experimental group submodule but the data
for sigmoid calculations include all data points for all indi-
viduals for each experimental group within the selected
experiment. When selecting the Internal Standard, an
additional series of charts (Figure 16) are presented after
normalization against the Internal Standard group.
B-cell response submodule allows to analyze results for
experimental groups across experiments by experiment
comparison functionality. This submodule oﬀers the pos-
sibility to evaluate, automatically or manually, sera across
experimental groups. An example is provided in Figure 17.
The outcome provides normalized sigmoids for all
selected experimental groups, quality charts and data
tables.
Molecular Signaturemodule
The main purpose of the Molecular Signature module is
to extract a gene subset, the expression of which varies
after immunization. Such gene signatures could then be
used as markers of vaccine eﬃcacy. Molecular Signature
module characterizes the change of gene expression of
Figure 14 B-cell responsemodule - sigmoid chart. An example sigmoid chart taken from B-cell responsemodule. The chart shows the sigmoids
calculated for several individuals for S1 serum titration.
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Figure 15 B-cell responsemodule - neutralization chart. The chart shows neutralization results across dilutions for Ag-speciﬁc pseudoparticles
(Ag-pp - blue color) and Control Ag-irrelevant pseudoparticles (CTR-pp - white color). Charts are taken from the Individual submodule of B-cell
responsemodule.
vaccinated individuals against that of control individu-
als. Input data for this module are results of microarray
experiments which are introduced into the system. The
organization of the experiment data is similar to that in
the other modules. Hence, a user deﬁnes an experiment,
experimental groups, and individuals within each exper-
imental group. For each individual, microarray results
can be introduced for various organ and cell types. Cur-
rently, the system is able to analyze Illumina, CodeLink &
Aﬀymetrix microarray data. Each experiment, as well as
experimental group, has a quality status which deﬁnes the
quality of the data (see Quality Control module section).
Gene expression analysis can be restricted to prede-
ﬁned gene lists of interest, created and managed by
users.
The analysis of microarray data can be done in Results
and Comparison of experiments submodules. Results sub-
module presents the comparison of gene expression of
a vaccinated group of individuals against the control
group, using graphical format (Figure 18). Comparison of
Figure 16 B-cell responsemodule - sigmoid-based antibody titer chart. An example chart taken from the Experimental group submodule
presenting the antibody titer values deduced from sigmoid regression for selected individuals. See GeVaDSs Manual for detailed description of
calculation [14].
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Figure 17 B-cell responsemodule - serum correspondence editor in Comparison of experiment sub-module. In case of a comparison across
experiments, the problem is that diﬀerent titration days can be speciﬁed in diﬀerent experiments. Therefore, the system cannot automatically
compare the data. The term Virtual Serum was introduced by Compuvac team to solve this dilemma. In the B-cell responsemodule, a user speciﬁes
which results should be compared. In other words, when the comparison is between experimental groups belonging to the same experiment, the
charts present results for each of the serum titration separately. When the user compares results of experimental groups from diﬀerent experiments,
the charts are created for each of the Virtual Sera assigned. In the provided example, two experiments with diﬀerent numbers of serum descriptions
taken at diﬀerent days (see VS1) are compared. This “Virtual Serum” editor allows to match data of the 14’th day of experiment E142-UPMC- EG4 with
the 15’th day of experiment E175-KI-EG2.
experiments submodule presents the comparison of gene
expression changes in several experiments simultaneously
(Figure 19).
Vector Challengemodule
Vector Challenge module measures the eﬃcacy of immu-
nization protocols. It stores survival, or protection, infor-
mation of vaccinated individuals challenged with live virus
(against which the vaccine, if eﬃcient, is expected to
protect the individual).
Again, Vector Challenge result parameter values can be
inserted by generating an MS Excel template ﬁle after
deﬁning necessary information about the experiment,
experimental groups and number of individuals within
each group. The template can be ﬁlled by the user by copy-
pasting from his/her worksheet and then uploading back
to the system. After checking for potential inconsisten-
cies, uploaded data will be inserted automatically. In case
of errors, a report is generated. The mechanism of tem-
plate generations and template uploading is similar to that
in T-cell and B-cell modules.
The following data analysis submodules have been
developed:
• Individual submodule, which allows the user to
analyze single individuals. Data can be presented in a
tabular way and as a chart.
• Experimental group submodule, which allows the
user to view an outcome of challenge results for a
selected experimental group presenting the average
values for individuals. Results are presented in a chart
as well as a data table (not shown).
• Experiment submodule, which allows the user to
view the outcome at the experiment level. Results are
presented in several useful formats using tables and
charts (Figure 20).
Evaluationmodule
The idea and implementation of the Evaluation module
is a unique solution in the current state of the art of
immunological experiments. The idea that lies behind this
module is to assess experiments using multicriteria anal-
ysis. Evaluation module provides an overall evaluation of
investigated vaccines and vectors. The evaluation process
establishes eﬀectiveness of a vaccine, based on the results
received for the monitored parameters for all types of
experiments (T-cell response, B-cell response, Molecular
Signature).
Each type of experiment has its own weight (it can be
adjusted by a user) and as a result of experiment compari-
son, the user can obtain separate scores for each particular
experiment, together with the global score (see Figure 21).
Multicriterial analysis can be applied by selecting exper-
iments that should be considered and by setting values
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Figure 18Molecular signaturemodule - comparison of gene expression value. The Figure presents a comparison of gene expression of a
vaccinated group of individuals against the control group. A spot represents a gene. Position of a spot is determined by the expression of a given
gene. Vertical position of a spot represents expression of the gene of the vaccinated group while horizontal position of a spot represents expression
of the gene of the control group. Filtering mechanism could be applied in order to remove from the analysis genes, which expression’s ratio is lower
than some threshold (the empty space on the diagonal of the chart).
of weights corresponding to particular experiment. The
quality of experiments is graded from A (the highest)
to F (the lowest). This matrix-based analysis provides a
standardized frame for comparing vaccine candidates and




An end-user demonstration is provided as Additional
ﬁle 1 in order to give a practical tutorial for GeVaDSs main
features. The data used for this demonstration example
are based on current experimental data produced during
the course of the CompuVac project; they are available
in GeVaDSs for demonstration purpose so that the cor-
responding analyses can be reproduced. This simulated
example of GeVaDSs illustrates how to test the poten-
tial strength of a newly isolated virus (i.e. PEV) as a new
vaccine platform by: (i) evaluating the potential of this
vaccine platform candidate and (ii) comparing it to other
available vector platforms already tested in GeVaDSs.
First, the three vector constructs to be tested (PEVdelta,
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Figure 19Molecular signaturemodule - comparison of gene expression changes. Presents the comparison of gene expression changes of
several experiments simultaneously.
PEVdelta-gp33, PEVdelta-VSVG) are deﬁned in GeVaDSs
(slides 3-7). Mice are then immunized with these con-
structs or CompuVac reference vector (Internal Standard)
(slides 8-12). The corresponding T-cell & B-cell immune
responses as well as transcriptome data are collected and
automatically entered in GeVaDSs database (slides 13-18).
Finally, the appropriate analysis reports are generated in
order to evaluate PEV vector performance (slides 19-24).
As a result PEV is positively evaluated as an eﬃcient vec-
tor platform (slide 25) (see Additional ﬁle 1). The diagram
illustrating the phases of data processing is presented in
the chart - see Additional ﬁle 2.
Conclusions
GeVaDSs, developed by the CompuVac consortium, oﬀers
a unique solution for improved development of novel
Vaccines by the ability to analyse and compare experi-
mental data from diﬀerent laboratories. The interactive
database contains standardized data related to a series
of recombinant vaccines (>100) covering most categories
of currently developed vaccine platforms (peptide, DNA,
viral-based, bacterial-based and VLPs). This data set may
serve as a core reference for vaccine developers. The
use of the CompuVac Internal standards allows for newly
generated data to be added and reliably compared with
Figure 20 Challenge responsemodule. An exemplary data graph taken from Challenge responsemodule. For each vector tested (as indicated on
the left), antibody titers (measured at days 14 and 30) and individual survival (as indicated on the right), are summarized.
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Figure 21 Evaluation score. As a result of experiment comparison user can obtain separate scores for each particular experiment, together with
the global score.
the core database. During the CompuVac project time-
frame, GeVaDSs has already allowed users to conduct
comparisons between diﬀerent vaccine types and initi-
ated novel vaccine design and vaccination regimens. For
example, GeVaDSs identiﬁed an adenovirus/DNA prime-
boost immunization scheme as more eﬃcient than the
conventional DNA/adeno prime-boost scheme for vacci-
nation against hepatitis C virus [9]. Besides monitoring
of T- and B-cell immune responses, vaccine eﬃcacy and
safety proﬁles were also analyzed by transcriptome studies
which allowed the system to generate molecular signa-
tures of diﬀerent vectors, and their clustering in vector
classes. Detailed analyses of these signatures is underway
to decipher the underlying networks/pathways correlat-
ing with vector activity (manuscript in preparation). We
believe that GeVaDSs, whose database is constantly grow-
ing, should contribute to rationalizing and speeding up
vaccine development.
GeVaDSs has aﬀorded integration of biological and
bioinformatics components of immunological experi-
ments. Together with other similar initiatives [7,10], the
system provides valuable evidence of the progress in this
area and delivers user friendly interface and tools for
future analysis of experiments. Recent successful sys-
tems biology approaches in the ﬁeld of immune/vaccine
response analysis advocate for larger initiatives and devel-
opment of standardized databases [11-13]. The ﬂexibil-
ity of GeVaDSs makes it possible to adapt the system
in a wider ﬁeld of usage than that speciﬁc to Com-
puVac. This might be of value for acquiring and ana-
lyzing datasets associated with translational research
investigation in medicine, where multiple parameters are
considered with increasing potential for integration of
transcriptome, proteome and other datasets, requiring
sophisticated bioinformatics-driven analysis, but overlap
with more conventional clinical measures. In particu-
lar, GeVaDSs is able to assess quantitative measures as
employed in clinical trial assays for validation concern-
ing reproducibility, inter-assay and inter-lab variation.
GeVaDSs therefore should contribute to shifting tradi-
tional and empirical vaccine development to systems
vaccinology [3].
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Availability and requirements
• Project name: GeVaDSs
• Project home page: http://gevads.cs.put.poznan.pl/,




• Operating system: Linux for server side
• Programming language: client side - Action Script
3.0 and Flex, server side - PHP, c/c++ with GNU
Scientiﬁc Library, Perl and R.
• Other requirements: client side - web browser with
Flash Player v. 9.0 or newer, server side - PostgreSQL,
Apache 2.0
• Any restrictions to use by non-academics: none
The full version of GeVaDSs is publicly available and any
researcher can use the system for free after registration.
However, the source code of the system is not publicly
available and there is no distributable version because
of the complexity of implemented modules. The system
consists of many connected modules written in many pro-
gramming languages and installing it is very complicated.
In special cases, we are ready to consider an installation of
the system for an interested user on his dedicated server.
Additional ﬁles
Additional ﬁle 1: A simulated example of GeVaDSs use. Testing the
potential of a newly isolated virus as a new vaccine platform.
Additional ﬁle 2: GeVaDSs workﬂow. The diﬀerent steps of the
GeVaDSs workﬂow are summarized in the light of the example provided in
Addition ﬁle 1.
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